An outlook on antigen-specific adoptive immunotherapy for viral infections with a focus on COVID-19.

ABSTRACT: Although not a standard-of-care yet, adoptive immunotherapeutic approaches have gradually earned a place within the list of antiviral therapies for some of fatal and hard-to-treat viral diseases. To maintain robust antiviral immunity and to effectively target the viral particles and virally-infected cells, immune cells capable of recognizing the viral antigens are required. While conventional vaccination can induce these cells in vivo; another option is to prime and generate antigen-specific immune cells ex vivo. This approach has been successfully trialed for virulent opportunistic viral infections after bone marrow transplantation. Amid the crisis of SARS-CoV2 pandemic, which has been followed by the success of certain early-authorized vaccines; some institutions and companies have explo

SUBMITTER: Monzavi SM 

PROVIDER: S-EPMC8214814 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature